- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about Weight Loss
Recent news which mentions Weight Loss
Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company
June 13, 2025
From Benzinga
From Benzinga
From Benzinga
Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies
June 11, 2025
From Benzinga
Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data
June 09, 2025
From Benzinga
Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy
June 09, 2025
From Benzinga
Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say
June 06, 2025
From Benzinga
Hims & Hers ZAVA Acquisition Deal Expands Its Market Opportunity By $52 Billion: Analyst
June 04, 2025
From Benzinga
Mounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market In $870-Million Deal
June 04, 2025
Tickers
LLY
From Benzinga
Why ReShape Lifesciences Stock Is Soaring Today: Key Drivers Behind Weight-Loss Company's Surge
June 03, 2025
Tickers
RSLS
From Benzinga
From Benzinga
Veru's Enobosarm Shows Muscle In Wegovy Combo Trial
May 28, 2025
From Benzinga
Novo Nordisk's Ozempic Weight Loss Jabs Could Boost UK Economy By $6 Billion, Study Finds
May 14, 2025
From Benzinga
Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs
May 14, 2025
From Benzinga
Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook
May 07, 2025
From Benzinga
Novo Nordisk's Weight Loss Blockbuster Faces Setback From US Compounding Surge, Forecast Trimmed
May 07, 2025
From Benzinga
CVS Caremark To Place Novo Nordisk's Wegovy On Preferred Coverage For GLP-1 Weight Loss Treatment
May 01, 2025
From Benzinga
Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform
April 29, 2025
From Benzinga
From Benzinga
Eli Lilly Positioned To Dominate Obesity Market With Oral Option, Analyst Initiates With Confidence
April 22, 2025
From Benzinga
Eli Lilly's Oral GLP-1 Drug Orforglipron Hits Phase 3 Goals In Diabetes Trial, Stock Soars
April 17, 2025
From Benzinga
Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models
April 15, 2025
From Benzinga
Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch
April 15, 2025
From Benzinga
EXCLUSIVE: Vivani Medical Collaborates With Okava To Expand Development Of GLP-1 Therapy For Dogs
April 15, 2025
From Benzinga
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.